Company Introduction

Juventas Cell Therapy Ltd (JUVENTAS) was founded in June 2018 with its headquarter at China Central Place, Chaoyang District, Beijing, and a R&D and transformation base for immune cell therapeutic drugs in Tianjin Huayuan Industrial Park. As a biotechnology company specializing in discovery of innovative immune cell therapeutic drugs, JUVENTAS is committed to building a whole industry chain business for immune cell therapeutic drugs, including R&D, manufacturing, and the sales.

Relying on the preliminary technical achievements of the domestic first-class hematology hospital and hematology research institute, JUVENTAS has accelerated the transformation of research results of cell therapeutic drugs such as CAR-T.

It has been continuously integrating domestic and foreign technology, talents and funds since its foundation. At present, the company’s first investigational new drug application for the cell therapeutic product CNCT19 has been officially accepted by the National Medical Products Administration. Comprehensive product pipelines will be developed and promoted constantly to provide effective treatment for malignant hematological neoplasms such as leukemia and lymphoma. JUVENTAS has already built a GMP immune cell drug R&D transformation facility of 1400 square meters in Tianjin Huayuan Industrial Park, and there is a 7,000-square-meter production base for GMP immune cell drugs under construction as well.

With an efficient R&D transformation platform, the company is capable of introducing safe, effective and accessible high-quality cell therapy products to Chinese patients, who will definitely benefit from the manufacturing and quality systems of our meticulous cell therapy products!

Management Team